Symptom and Allergy Load Drives Food Allergy Distress
METHODOLOGY:
Researchers conducted a cross-sectional online survey involving 1329 adults (mean age, 38.1 years; 70.2% women) and 1373 caregivers (mean age, 37.6 years; 75.1% women) of children with food allergy to identify factors associated with specific types of food allergy‐related psychological distress.
Participants reported types of food allergy-related distress experienced by themselves or their children.
TAKEAWAY:
Female adults (mean difference, -3.74) and female caregivers (mean difference, -5.82; P < .001 for both) were more likely to experience multiple types of food allergy-related psychological distress than male adults.
< .001 for both) were more likely to experience multiple types of food allergy-related psychological distress than male adults. In children and caregivers, the likelihood of reporting more types of distress increased with allergy duration, whereas in adults and caregivers, it rose with prescriptions of adrenaline autoinjectors ( P < .001 for all).
< .001 for all). Adults, children, and caregivers with a higher number of food allergies, more comorbid conditions, or more symptoms of food allergy were more likely to experience psychological distress ( P < .001 for all).
< .001 for all). Adults and caregivers from Australia, Brazil, Canada, and the UK consistently reported higher rates of psychological distress than those from European countries or the US.
IN PRACTICE:
'Adults may find it beneficial to learn how to recognize the symptoms of anaphylaxis, enabling them to more accurately assess their level of risk. In families with an allergic child, caregivers require more psychological support when the child is younger,' the authors wrote.
SOURCE:
R.C. Knibb, PhD, with Aston University, Birmingham, England, was the corresponding author of the study, which was published online in Clinical and Translational Allergy.
LIMITATIONS:
This study lacked a validated distress scale, and the perceived severity of food allergy was not assessed. Participants were mostly White, women, and university-educated, limiting the generalizability of the findings. Additionally, the online recruitment method and requirement for internet access likely introduced selection bias.
DISCLOSURES:
This study was funded by Novartis, Aimmune Therapeutics, the National Peanut Board, and the European Academy of Allergy and Clinical Immunology. Some authors reported receiving research funding, grants, personal fees, or honoraria from and having other ties with various organizations and pharmaceutical companies, including some of the funding sources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Spike in ADHD medication reports
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said.
Yahoo
17 minutes ago
- Yahoo
Women's symptoms 'overlooked' in menopausal stages
Women going through perimenopause are experiencing debilitating hot flushes and night sweats that are often untreated, as a study reveals the prevalence of symptoms during hormonal transitions. Perimenopause is a transitional period before menopause, where levels of oestrogen begin to decrease, bringing with it a range of symptoms. A first of its kind study of more than 5500 women by Monash University published in The Lancet Diabetes and Endocrinology examined the similarities and differences in symptoms across the stages of menopause. Almost 40 per cent of perimenopausal women in the study experienced debilitating vasomotor symptoms (VMS) such as hot flushes and night sweats. While it was already known that VMS symptoms were typical in menopause, the study showed a new onset was highly specific to perimenopause, senior author Susan Davis said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. "While other symptoms might emerge in the perimenopausal stage, they lack specificity to that stage as these other symptoms are also common in pre-menopausal women." A major finding in the study was that women with regular cycles but changed menstrual flow and VMS who are classified as pre-menopausal have a similar severity of symptoms as perimenopausal women. "This finding supports the likelihood of perimenopause commencing before menstrual cycles vary by at least a week, and that women whose periods have become much heavier or much lighter and who also have VMS should be considered as having entered their perimenopause," Professor Davis said. The research was expected to transform women's health treatment, particularly in menopause, which had been overlooked for too long, Monash Women's Health Alliance chair Jill Hennessy said. "Too many go untreated for debilitating symptoms like hot flushes and night sweats," she said. "By defining the symptoms that truly mark this transition, this study empowers women and clinicians alike with better knowledge and tools to improve women's health and wellbeing." The study authors hoped the findings would improve how medical professionals identified and managed transitions in menopause. Many women were overlooked in being classified within a menopausal stage if they had regular cycles or no longer menstruated due to a hysterectomy, first author Rakib Islam said. "Our findings support a more symptom-based approach, enabling earlier recognition of perimenopause and more timely care," he said.
Yahoo
an hour ago
- Yahoo
Aussie's daily swim leads to incredibly rare island discovery: 'Amazing'
One sunny morning last year, Lawrence Scheele wandered down to his local beach for a swim — something he does most days. However, just moments after he waded into the bright blue water, the Australian marine biologist realised this dip was not like any other. 'I noticed this clam that I've never seen before, and it had a really intricate and intriguing colouration to it that I thought looked really distinct from any of the other species we have around the island,' Scheele, who has spent the past several years documenting Magnetic Island's marine life for his upcoming scientific field guide, told Yahoo News. After snapping some photos and jotting down the creature's coordinates in Alma Bay, Scheele went back home and tried to match it to a documented species. 'I looked further into it and thought it was a Noah's giant clam (tridacna noae),' he explained. However, given the species had never been recorded on Australia's east coast or in the Great Barrier Reef, he wasn't quite sure. 'Lucky for me, one of the world leading experts of giant clams lives down the road. I went over to his house, and said 'Hey Rick, I think I found this rare clam'.' Despite his initial disbelief, after reviewing the photographs, Dr Richard Braley, known affectionately as 'The Giant Clam Man', excitedly confirmed it was indeed a Noah's giant clam. 'He was just so surprised,' Scheele told Yahoo, adding that Dr Braley described the observation as 'amazing'. 📸 Extremely rare moment off Aussie island ends search for 'cryptic' species 🦈 Locals in awe as rarely-seen creature washes up on remote beach 🌊 Incredible footage of special creature 'very rarely seen in Australia' Noah's giant clam recorded on Australia's east coast for first time The species, which has a broad distribution in the Indo-Pacific, was previously known locally to only live off Western Australia's tropical coast — until now. 'It's presumably the first sighting and definitely the first official recorded sighting [of a Noah's giant clam] on the east coast of Australia,' Scheele said. Following the surprising revelation in January 2024, the marine biologist and Dr Braley teamed up with Dr Thane Militz, a project scientist with the Australian Centre for Pacific Islands Research (ACPIR), to draft a study confirming the species' geographic distribution now includes the Great Barrier Reef. It was published this year. The discovery off Queensland's Magnetic Island 'affirms that a review of past population assessments and demographic parameters for giant clams within the Great Barrier Reef Marine Park (GBRMP) is now required', the study states. It's believed previous surveys 'might have been compromised due to inadvertent taxonomic confusion', with the experts believing it's unlikely the species would be restricted to the island. Sad twist of fate for unique giant clam Dr Braley told Yahoo he expects sightings of the colourful creatures to now occur both north and south of the tourist hotspot. 'It was an honour to have the first sighting here on our beautiful inshore reef island,' he said. 'We all as citizen scientists need to keep an open eye for the unusual when visiting the reef.' Unfortunately, the clam spotted by Scheele was later killed by ex-Tropical Cyclone Kirrily. 'I have not seen another Noah's giant clam, but I do now keep my eye out for them,' the marine biologist said. 'It's just so amazing to be based in such a beautiful part of the world and have access to all these fringing coral reefs that are just teeming with life, and they're also quite poorly studied,' Scheele added. 'There's so much diversity here that people don't know about.' Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
